EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kuros Biosciences's enterprise value is CHF981.17 Mil.
Kuros Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was CHF-0.56 Mil. Therefore, Kuros Biosciences's EV-to-EBITDA for today is -1,748.97.
The historical rank and industry rank for Kuros Biosciences's EV-to-EBITDA or its related term are showing as below:
LTS:0RHR'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1855.23 Med: -2.8 Max: 2.95
Current: -1748.97
During the past 13 years, the highest EV-to-EBITDA of Kuros Biosciences was 2.95. The lowest was -1855.23. And the median was -2.80.
LTS:0RHR's EV-to-EBITDA is ranked worse than 100% of 496
companies
in the Medical Devices & Instruments industry
Industry Median: 15.76
vs LTS:0RHR: -1748.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Kuros Biosciences EV-to-EBITDA Historical Data
The historical data trend for Kuros Biosciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kuros Biosciences's EV-to-EBITDA
For the Medical Devices subindustry, Kuros Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuros Biosciences's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kuros Biosciences's EV-to-EBITDA falls into.
Kuros Biosciences's current Enterprise Value is CHF981.17 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was CHF-0.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuros Biosciences (LTS:0RHR) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kuros Biosciences's PE Ratio (TTM) for today is calculated as:
Kuros Biosciences's share price for today is CHF26.25095.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kuros Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was CHF-0.103.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Kuros Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of inventive products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LTS:0RHR has been successfully added to your 